novo nordisk oral semaglutide says works in diabetic kids Novo Nordisk wins EU approval

While its long-term safety and efficacy are still under investigation, the Phase II results provide compelling evidence that this triple agonist could revolutionize the way we approach obesity and its associated health risks

Excellent head-to-head comparison of current and emerging GLP-1 receptor agonists weight loss medications by Ahmad Bahareth Simple comparison between the new Weight loss medication in 2026 The most likely to come sooner to the market is as follows: Oral Wegovy Then Weekly 7.2 SC Then Foundayo at all doses

The standard weight-loss follow-up appointment typically focuses on glycemic markers, blood pressure, cholesterol, and overall weight change - not DXA-confirmed bone density or lean mass composition

Week 3 (escalate): 7.5 mg = 0.75 mL (75 units)

5 The sudden lower concentration of glucose within the plasma creates a pressure gradient, causing water to move from the interstitium to the lower-pressure space within blood vessels